Generate Biomedicines, Inc. (GENB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Based on dividend-adjusted daily data since Feb 27, 2026, GENB's average daily return is +0.30%, while the average monthly return is +2.72%. At this rate, an investment would double in approximately 2.2 years.

Historically, 60% of months were positive and 40% were negative. The best month was Jun 2026 with a return of +25.5%, while the worst month was Feb 2026 at -15.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 2 months.

On a daily basis, GENB closed higher 53% of trading days. The best single day was Jun 4, 2026 with a return of +13.9%, while the worst single day was May 18, 2026 at -18.7%.

Generate Biomedicines, Inc. has an annualized alpha of 61.80%, beta of 1.41, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since February 27, 2026.

• This stock captured 23.25% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -67.30%) - a profile typical of hedging or uncorrelated assets.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Generate Biomedicines, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Generate Biomedicines, Inc. was 26.20%, occurring on Jun 2, 2026. Recovery took 15 trading sessions.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Generate Biomedicines, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Generate Biomedicines, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.